Comparison
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Androgens Excess and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
A condition where an XX individual has excess male hormones causing atypical genital development. It affects both newborns and older individuals. Treatment may involve hormone management and surgical options.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
0-null
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
reproductive
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
endocrine
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-androgens-excess-C5680227 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development in an XX individual is the described core feature. | Not specifically described; congenital features may vary. | High |
| Neurodevelopment | Developmental delay or intellectual disability is not established by the source. | Developmental delay and intellectual disability are associated features. | High |
| Hormone pattern | Excess androgen effect is central, but exact laboratory cutoffs are not supplied. | A primary androgen-excess pattern is not described. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227 when
XX karyotype with atypical genital development
This matches the supplied reproductive and endocrine description.
High
Clinical concern for androgen excess
Hormone evaluation may be relevant, but an abnormal result is not itself a diagnosis.
Moderate
Need for sex-development care
Management may include hormone care and discussion of surgery; decisions require specialists.
Moderate
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with congenital anomalies
This pattern fits the described genetic syndrome better than isolated genital atypicality.
Moderate
Suspected chromosomal copy-number change
The condition is defined by missing material at 3q13.
High
Broad multisystem congenital presentation
Features may extend beyond the reproductive system, although exact features are not established here.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX is part of the concept name. | Karyotype may be normal because a microdeletion can be missed. | A normal karyotype does not exclude either condition; clinician correlation is required. |
| Chromosomal microarray | No 3q13 deletion is implied by the source. | May identify missing 3q13 material. | A detected deletion supports the genetic diagnosis but does not define all clinical effects. |
| Androgen-related endocrine testing | May show androgen excess; exact cutoffs are not established here. | No characteristic androgen abnormality is supplied. | Abnormal hormone results require specialist interpretation and are not a complete diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Androgens Excess C5680227
- Outcome
- Chronic course is described, but long-term outcome is not established.
- Factors
- Genital findings, hormone pattern, timing of care, and individual goals may matter.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Chronic course with variable developmental and congenital effects is expected.
- Factors
- Deletion extent, associated anomalies, and developmental support may influence outcome.
Time frame: Often recognized in infancy or childhood, but onset details are incomplete.
Prognosis should be individualized; no mortality or exact outcome data are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Genital and reproductive concerns | Atypical genital development may require individualized endocrine or surgical care. Not specifically established in the source. Potential interventions and outcomes vary and are not quantified here. |
| Developmental disability | Not established by the supplied description. Intellectual disability and developmental delay are associated. Severity and functional impact vary; no prevalence is supplied. |
| Congenital anomalies | Primarily described as a sex-development condition. Various congenital features may occur. The exact anomaly pattern is not established by this source. |
Patient education highlights
- HighDifferent causes
One condition centers on androgen excess in an XX individual; the other is caused by missing chromosome 3q13 material.
- HighSpecialist interpretation
Genetic and hormone findings should be explained by qualified clinicians; an abnormal test is not automatically a diagnosis.
- MediumIndividualized care
Hormone management, surgery, developmental support, or other care may be discussed, but no universal plan or dose is established here.